Study end points
| End point . | dUCB % (95% CI) . | MRD % (95% CI) . | MUD % (95% CI) . | MMUD % (95% CI) . |
|---|---|---|---|---|
| LFS at 5 y | 51 (41-59) | 33 (26-41) | 48 (40-56) | 38 (25-51) |
| ≤ 45 y | 51 (41-59) | 31 (21-40) | 50 (41-58) | 34 (21-48) |
| Relapse at 5 y | 15 (9-22) | 43 (35-52) | 37 (29-46) | 35 (21-48) |
| ≤ 45 y | 16 (9-23) | 52 (41-63) | 37 (29-46) | 39 (24-54) |
| Disease free* | 17 (9-25) | 42 (33-51) | 30 (21-39) | 32 (17-47) |
| NRM at 5 y | 34 (25-42) | 24 (17-39) | 14 (9-20) | 27 (15-39) |
| Acute GVHD at 100 d | ||||
| Grade II-IV | 60 (50-70) | 65 (57-73) | 80 (70-90) | 85 (68-100) |
| Grade III-IV | 22 (15-29) | 13 (9-18) | 14 (9-20) | 37 (23-50) |
| Chronic GVHD at 2 y | 26 (15-35) | 47 (39-55) | 43 (34-52) | 48 (32-64) |
| End point | Median dUCB (range) | Median MRD (range) | Median MUD (range) | Median MMUD (range) |
| Neutrophil recovery at 45 d | 26 (13-45) | 16 (11-39) | 19 (11-39) | 18.5 (8-33) |
| Platelet recovery at 100 d | 53 (30-99) | 20 (9-63) | 21 (10-95) | 21 (10-98) |
| End point . | dUCB % (95% CI) . | MRD % (95% CI) . | MUD % (95% CI) . | MMUD % (95% CI) . |
|---|---|---|---|---|
| LFS at 5 y | 51 (41-59) | 33 (26-41) | 48 (40-56) | 38 (25-51) |
| ≤ 45 y | 51 (41-59) | 31 (21-40) | 50 (41-58) | 34 (21-48) |
| Relapse at 5 y | 15 (9-22) | 43 (35-52) | 37 (29-46) | 35 (21-48) |
| ≤ 45 y | 16 (9-23) | 52 (41-63) | 37 (29-46) | 39 (24-54) |
| Disease free* | 17 (9-25) | 42 (33-51) | 30 (21-39) | 32 (17-47) |
| NRM at 5 y | 34 (25-42) | 24 (17-39) | 14 (9-20) | 27 (15-39) |
| Acute GVHD at 100 d | ||||
| Grade II-IV | 60 (50-70) | 65 (57-73) | 80 (70-90) | 85 (68-100) |
| Grade III-IV | 22 (15-29) | 13 (9-18) | 14 (9-20) | 37 (23-50) |
| Chronic GVHD at 2 y | 26 (15-35) | 47 (39-55) | 43 (34-52) | 48 (32-64) |
| End point | Median dUCB (range) | Median MRD (range) | Median MUD (range) | Median MMUD (range) |
| Neutrophil recovery at 45 d | 26 (13-45) | 16 (11-39) | 19 (11-39) | 18.5 (8-33) |
| Platelet recovery at 100 d | 53 (30-99) | 20 (9-63) | 21 (10-95) | 21 (10-98) |
Survivors who were disease free at day +100 after transplantation.